Phreesia, Inc. (PHR) is a publicly traded Healthcare sector company. As of May 21, 2026, PHR trades at $8.70 with a market cap of $560.91M and a P/E ratio of 219.88. PHR moved -3.65% today. Year to date, PHR is -48.31%; over the trailing twelve months it is -65.28%. Its 52-week range spans $7.77 to $32.76. Analyst consensus is buy with an average price target of $14.43. Rallies surfaces PHR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Phreesia Downgraded by Four Brokers, Cuts 2027 Outlook by $35M–$39M: Four major brokerages downgraded Phreesia shares after the company cut its fiscal 2027 revenue outlook by $35–$39 million to $510–$520 million, triggering a 26% premarket slide. The company maintained its adjusted EBITDA forecast of $125–$135 million despite forecasting low-single-digit organic growth versus prior 8–10% expectations.
| Metric | Value |
|---|---|
| Price | $8.70 |
| Market Cap | $560.91M |
| P/E Ratio | 219.88 |
| EPS | $0.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.76 |
| 52-Week Low | $7.77 |
| Volume | 83 |
| Avg Volume | 0 |
| Revenue (TTM) | $480.59M |
| Net Income | $2.31M |
| Gross Margin | 0.00% |
16 analysts cover PHR: 0 strong buy, 10 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.43.